Be Diane Raceasi
FDA investigator
Appears on 1 document from 2019, mostly at sites in California. Most often cites general requirements (21 CFR 211.160).
- 1
- Documents on file
- 20.0
- Observations per 483
- 2019
- First seen
- 2019
- Most recent
What they cite most
From 20 observations- 21 CFR 211.160General requirements3
- 21 CFR 211.42Design and construction features3
- 21 CFR 211.100Written procedures; deviations2
- 21 CFR 211.110Sampling and testing of in-process materials and drug products2
- 21 CFR 211.113Control of microbiological contamination2
- 21 CFR 211.84Testing and approval or rejection of components, drug product containers, and closures2
Activity by year
2019: 1
Where
California 1
Often inspects with
Is Be Diane Raceasi coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
1 document, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2019-05-02 | 483 Tanvex BioPharma USA, IncMay 2, 2019 · San Diego, California | San Diego, California | 20 |
About this profile
What does Be Diane Raceasi inspect?
Be Diane Raceasi appears on 1 document on file covering 1 site, mostly in California.
What do they cite most often?
21 CFR 211.160 (general requirements), followed by 21 CFR 211.42 and 21 CFR 211.100.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Be Diane Raceasi is dated May 2, 2019.